Get the Stockscreener App
0.3736
7.48%
-0.0302
After Hours:
.37
-0.0036
-0.96%
Senti Biosciences Holdings Inc stock is traded at $0.3736, with a volume of 559.31K.
It is down -7.48% in the last 24 hours and down -65.72% over the past month.
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
See More
Previous Close:
$0.4038
Open:
$0.4002
24h Volume:
559.31K
Relative Volume:
2.25
Market Cap:
$11.64M
Revenue:
$38,000
Net Income/Loss:
$-51.55M
P/E Ratio:
-0.1945
EPS:
-1.9207
Net Cash Flow:
$-37.07M
1W Performance:
-13.88%
1M Performance:
-65.72%
6M Performance:
-64.75%
1Y Performance:
-80.64%
1-Day Range:
$0.3612
$0.42
1-Week Range:
$0.3612
$0.5098
52-Week Range:
$0.3612
$2.88
Senti Biosciences Holdings Inc Stock (SNTI) Company Profile
Name
Senti Biosciences Holdings Inc
Sector
Industry
Phone
(650) 239-2030
Address
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
Compare SNTI vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNTI
Senti Biosciences Holdings Inc
|
0.3736 | 12.58M | 38,000 | -51.55M | -37.07M | -1.9207 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Senti Biosciences Holdings Inc Stock (SNTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-25 | Initiated | H.C. Wainwright | Buy |
| Jun-06-25 | Initiated | Laidlaw | Buy |
| Oct-07-22 | Initiated | Morgan Stanley | Equal-Weight |
Senti Biosciences Holdings Inc Stock (SNTI) Latest News
Senti Biosciences Holdings Inc. (SNTI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
SNTI|Senti Biosciences Inc|Price:0.448| - TradingKey
$Senti Biosciences (SNTI.US)$ - Moomoo
Senti Biosciences Holdings, Inc. SEC Filing (Jul 21, 2026) - Stock Titan
Senti Biosciences (SNTI) outlines CVR-only merger, reverse split and note share issuance - Stock Titan
Form 13D/A Senti Biosciences Holdings For: 16 July By Investing.com - Investing.com Nigeria
Form S-3/A Senti Biosciences Holdings Inc For: 16 July - Investing.com Nigeria
Form S-3/A Senti Biosciences Holdings Inc For: 16 July By Investing.com - Investing.com South Africa
Senti Biosciences (SNTI) backer plans merger and $6M funding - Stock Titan
Senti Biosciences to spin off gene therapy unit for CVR - Investing.com
Senti Biosciences Holdings Announces Strategic Spin-Off of Gene-Circuit Pipeline and Plans Focus on Regulator Dial Platform - Quiver Quantitative
Senti Biosciences to Divest Operating Business to Celadon Affiliate; Holders Get Up to $60M CVRs - TradingView
Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Te - Yahoo Finance
Senti Bio Stockholders Could Receive Up to $60M From SENTI-202 - Stock Titan
SNTI Should I Buy - Intellectia AI
Price to sales forward of Senti Biosciences Holdings, Inc. – NASDAQ:SNTI - TradingView
Price to book forward of Senti Biosciences Holdings, Inc. – NASDAQ:SNTI - TradingView
Enterprise value to EBITDA forward of Senti Biosciences Holdings, Inc. – NASDAQ:SNTI - TradingView
Enterprise value to EBIT forward of Senti Biosciences Holdings, Inc. – NASDAQ:SNTI - TradingView
Senti Biosciences Holdings Inc Actuals & Estimates (NASDAQ:SNTI) - TradingView
SNTI Forecast — Price Target — Prediction for 2027 - TradingView
Senti Biosciences (SNTI) registers 15.97M shares tied to May 2026 notes - Stock Titan
Senti Biosciences Inc (SNTI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SNTI Q1 2026 Earnings: Modest EPS Beat Amid Development ProgressEarnings Call Transcript - dars.gov.et
Senti Biosciences Inc (SNTI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
The Radoff-JEC Group Highlights Seer Inc.’s and Chairman and CEO Omid Farokhzad, M.D.’s History of Value Destruction - Business Wire
SNTI Stock Price, Quote & Chart | SENTI BIOSCIENCES HOLDINGS I (NASDAQ:SNTI) - ChartMill
SNTISenti Biosciences Holdings Inc Options - Finviz
Senti Biosciences Inc. (SNTI) Stays Near Key Support Following Modest UptickTake Profit Levels - The Legal Advocate
Senti Biosciences (SNTI) sells $10M notes, outlines up to $60M SENTI-202 CVR - Stock Titan
Senti Biosciences Stock Near $1: FDA Signal and Cash Test Put SNTI Back on Watch - Bez Kabli
Senti Biosciences Inc. Q1 2026 Earnings: Narrowing Losses and Gene Circuitry ProgressCFO Commentary Report - Newser
Senti Bio Advances SENTI-202 to Pivotal Trial With Donor X Selection Strategy - The Clinical Trial Vanguard
Senti Biosciences Holdings, Inc.Common Stock (NQ: SNTI - The Chronicle-Journal
Senti Biosciences Faces Severe Refinancing and Liquidity Risks from Costly Note Structure - TipRanks
SNTI Maintained by Chardan Capital -- Price Target Raised to $12 - GuruFocus
Chardan Raises Price Target on Senti Biosciences to $12 From $11, Keeps Buy Rating - Moomoo
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program - Sahm
Senti Biosciences Secures FDA Support for SENTI-202 Donor Selection Strategy in AML - The Clinical Trial Vanguard
Senti Biosciences (NASDAQ: SNTI) flags going concern, lines up $40M convertible note financing - Stock Titan
Senti Biosciences Advances SENTI-202 to Pivotal Phase for AML, Secures $40M Financing, and Reports Reduced Q1 2026 Loss - Minichart
Senti Biosciences 1Q Loss $4.22M >SNTI - Moomoo
Senti Biosciences Advances SENTI-202 With New FDA Support - TipRanks
Senti Bio plans pivotal trial for AML therapy after FDA meeting - Investing.com
Senti Biosciences Holdings announces positive FDA RMAT meeting on registrational clinical and CMC strategy - marketscreener.com
Senti Bio plans pivotal trial for AML therapy after FDA meeting By Investing.com - Investing.com South Africa
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy - TradingView
Senti Biosciences Secures Up to $40 Million Financing and FDA Endorsement for SENTI-202 in Relapsed/Refractory Acute Myeloid Leukemia - Quiver Quantitative
Senti Bio (NASDAQ: SNTI) wins FDA RMAT backing and lines up $40M funding - Stock Titan
Senti Biosciences 1Q Loss/Shr 14c >SNTI - Moomoo
Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase - Yahoo Finance
Senti Biosciences Holdings Inc Stock (SNTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):